NCT01991366|Withdrawn
Study Stopped
lack of funding
Loading search results
lack of funding
Sponsor study identifier
observational
0
1 country
1
Study Start
October 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2021
Actual (reported)The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction in a large tertiary referral center. It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is superior to unfractionated heparin alone or bivalirudin alone. Additionally, after propensity matching this superiority remains.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2021
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 18, 2013
Actual (reported)November 25, 2013
Actual (reported)October 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 2021
Actual (reported)All-cause mortality and composite or Q-wave myocardial infarction
6-month rates of all-cause mortality and the composite of all-cause mortality or Q-wave myocardial infarction.
Chart review 6 months after PCI
TIMI major bleeding
During hospital stay; average stay is less than 48 hours
Receive eptifibatide pre PCI
Receive eptifibatide during PCI
Receive no eptifibatide
Patients who underwent primary Percutaneous Coronary Intervention at Washington Hospital Center since September 2000 and received eptifibatide pre-or during PCI or have received no eptifibatide.
Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
Ron Waksman, MD
Medstar Health Research Institute
0 participants (actual enrollment reported by the registry).
First Submitted
November 18, 2013
First Posted
November 25, 2013
Study Start
October 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Resistance STEMI Study
Contact the study team to confirm eligibility.
Primary Completion
October 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2021
Actual (reported)Last Updated
July 2, 2021
Record last verified: 2021-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: